4D Surgical funding, valuation and investors

Product & use cases

Research-stage technical/clinical path, not a commercial hands-on demo: (1) neurosurgical team uses MRI to localize a deep-brain target and observe anatomy; (2) MRI-compatible actuator and motor controls would operate a robot within the scanner's strong magnetic field, without the traditional ferromagnetic motor design; (3) robot could be guided by repeated real-time imaging instead of exclusively preoperative imaging to account for brain-shift; (4) candidate applications include minimally invasive placement of electrodes or localized therapies; (5) engineering must prove electromagnetic compatibility, tracking accuracy and sterility in laboratory and preclinical conditions; (6) regulatory clearance/authorization, clinical trials, hospital procurement, training and reimbursement would be required before routine patient deployment. These are proposed technical and validation gates, not proof that every step has been demonstrated in patients.

• Potential live MRI-guided placement of electrodes or therapeutic devices in neurosurgery, subject to validation.
• Future delivery of cell/gene therapies to precise brain regions where conventional access limits distribution, not an approved indication.
• Research platform for comparing image-guided navigation and robotic placement fidelity in controlled settings.

Key facts

• $8M seed disclosed November 12, 2026 in a participant investor announcement from Version One Ventures; lead investor role not proven by company/participant releases.
• Scientific objective: real-time MRI-guided, compatible robotics for delivery of electrodes, devices and therapies into the brain.
• Existing patent applications describe ambient-field motor controls; patent publication is not clinical clearance or patient evidence.
• Public sources do not establish FDA authorization, clinical efficacy, routine patient use, product pricing or revenue.

Competitive landscape

Edge: MRI-compatible actuator/control design seeks to combine imaging feedback and robot navigation inside the scanner. Brain shift makes static preoperative navigation imperfect, but superior outcomes and scalability are hypotheses rather than completed clinical claims.

Participating investor Version One and company investor logos establish funding participants, but do not identify a lead or financing date separate from disclosure. Company founder biographies and Creative Destruction Lab description support the engineering concept. Their claims about precise universal brain access are forward-looking; no peer-reviewed intervention outcomes, FDA authorization, or priced hospital procurement terms were established. Published patent applications are not proof of patent issuance, freedom to operate or efficacy. Hospitals would evaluate MRI workflow disruption, sterilization, procedure duration, clinical endpoints, insurer reimbursement and capital cost.

• Medtronic StealthStation adjacent

  Established navigation system, but not the same live MRI-compatible in-scanner robotic actuator proposition.

• ROSA ONE Brain (Zimmer Biomet) adjacent

  Robotic neurosurgical guidance; operational modality and imaging workflow differ.

• ClearPoint Neuro direct

  MRI-guided neurosurgical intervention platform, meaningful comparator for image-guided access and clinical deployment.

• Neuralink surgical robot adjacent

  Robotic electrode implantation architecture with a different procedure and product development pathway.

Market / IPO context